Overview

Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)

Status:
Completed
Trial end date:
2002-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the relative bioavailability of Naproxen delayed-release tablets (375 mg).
Phase:
Phase 1
Details
Lead Sponsor:
Sandoz
Treatments:
Naproxen